HyBryte(TM) Treatment Studies Presented at Two Medical Conferences in March

Stock Information for Soligenix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Soligenix Inc.

Positive Outcome in 75% of CTCL Patients Treated with HyBryte(TM) for 18 Weeks
IBN Initiates Coverage of Soligenix Inc.
Soligenix Announces Publication Demonstrating CiVax(TM) Booster Induces Rapid Broad Protection Against COVID-19 Variants
Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results
Soligenix to Present at BIO CEO & Investor Conference
Soligenix to Present at Upcoming Investor Conferences
HyBryte(TM) Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte(TM) for the Treatment of Cutaneous T-Cell Lymphoma

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.